Compare MBUU & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBUU | VALN |
|---|---|---|
| Founded | 1982 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 541.4M | 495.5M |
| IPO Year | 2013 | 2021 |
| Metric | MBUU | VALN |
|---|---|---|
| Price | $28.32 | $5.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $32.20 | $15.50 |
| AVG Volume (30 Days) | ★ 302.1K | 19.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 127.74 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $807,561,000.00 | N/A |
| Revenue This Year | $2.14 | N/A |
| Revenue Next Year | $12.78 | $93.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $23.84 | $5.04 |
| 52 Week High | $39.65 | $12.25 |
| Indicator | MBUU | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 57.17 | 39.10 |
| Support Level | $28.10 | N/A |
| Resistance Level | $29.79 | $5.52 |
| Average True Range (ATR) | 1.32 | 0.19 |
| MACD | 0.25 | 0.00 |
| Stochastic Oscillator | 77.47 | 10.33 |
Malibu Boats is a designer and manufacturer of power boats in the United States. It is a market leader in performance sport boats, sold under its Malibu and Axis brands. It acquired Cobalt Boats, a producer of sterndrive boats, in 2017, and Pursuit Boats, which makes high-end offshore and outboard motorboats, in 2018. In 2021, it purchased Maverick Boat Group, a seller of flat fishing boats, with exposure to bay, dual console, and center console boats. Most recently, in 2026, it tied up with Saxdor Yachts, focused on adventure dayboats. Malibu has also expanded into boat trailers and accessories, and in 2020, began producing its own engines for its performance sport boats.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.